MedTrace Logo

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment

NCT00993876 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2009-10-14

No results posted yet for this study

Summary

Cognitive deficits in major depression seem explicable by the well-recognized concept of impaired neuroplasticity in mood disorders. This concept initially emerged from preclinical evidence that antidepressants phosphorylate and therefore activate the cyclic AMP response element binding protein (CREB) that is essential for synaptic plasticity. Nevertheless, the question remains whether the activation of CREB by antidepressants is relevant for the remission of cognitive deficits in patients. We addressed this issue by investigating the cognitive improvement during treatment with either citalopram or reboxetine because these antidepressants are different in their capacity to increase phosphorylated CREB (pCREB). Besides the pharmacological treatment groups, another group of patients was treated exclusively with psychotherapy.

Conditions

  • Cognitive Performance in Major Depression

Interventions

DRUG

citalopram

20 to 30 mg per day for 4 weeks

DRUG

reboxetine

4 to 8 mg per day for 4 weeks

BEHAVIORAL

interpersonal psychotherapy

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • Zentrum für Integrative Psychiatrie

    lead OTHER

Principal Investigators

  • Jakob M. Koch, M.D. · Zentrum für Integrative Psychiatrie, Kiel, Germany

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00993876 on ClinicalTrials.gov